Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H21NO3.H2O |
Molecular Weight | 317.3795 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.[H][C@@]12OC3=C4C(C[C@H]5N(C)CC[C@@]14[C@@]5([H])C=C[C@@H]2O)=CC=C3OC
InChI
InChIKey=WRRSFOZOETZUPG-FFHNEAJVSA-N
InChI=1S/C18H21NO3.H2O/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19;/h3-6,11-13,17,20H,7-9H2,1-2H3;1H2/t11-,12+,13-,17-,18-;/m0./s1
Molecular Formula | C18H21NO3 |
Molecular Weight | 299.3642 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Codeine is an opiate used to manage mild to moderate pain severe enough to require an opioid. Codeine is a selective agonist for the mu opioid receptor and has an affinity to delta and kappa-opioid receptors. In some countries, this drug is regulated under various narcotic control laws, because its chronic use can cause physical dependence. In others, it is available without a medical prescription in combination with paracetamol.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL233 |
6.1 µM [EC50] | ||
Target ID: P41145 Gene ID: 4986.0 Gene Symbol: OPRK1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/7885194 |
|||
Target ID: P41143 Gene ID: 4985.0 Gene Symbol: OPRD1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/7885194 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CAPITAL AND CODEINE Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Dystonia as acute adverse reaction to cough suppressant in a 3-year-old girl. | 2001 |
|
Determination of opiates in serum, saliva and hair addicted persons. | 2001 |
|
Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. | 2001 |
|
Pharmacological control of cough. | 2001 Apr |
|
The use of compound 48/80 and codeine phosphate as positive controls for intradermal skin testing in dogs. | 2001 Apr |
|
Precipitated withdrawal following codeine administration is dependent on CYP genotype. | 2001 Aug 17 |
|
Effect of penicillin on postoperative endodontic pain and swelling in symptomatic necrotic teeth. | 2001 Feb |
|
Opioids for chronic nonmalignant pain. Attitudes and practices of primary care physicians in the UCSF/Stanford Collaborative Research Network. University of California, San Francisco. | 2001 Feb |
|
Dose-related effects of controlled release dihydrocodeine on oro-cecal transit and pupillary light reflex. A study in human volunteers. | 2001 Jan |
|
Inhibition by glucocorticoids of the mast cell-dependent weal and flare response in human skin in vivo. | 2001 Jan |
|
[Chronic pain in geriatrics]. | 2001 Jun |
|
Analysis of cocaine, benzoylecgonine, codeine, and morphine in hair by supercritical fluid extraction with carbon dioxide modified with methanol. | 2001 Jun 1 |
|
Codeine phosphate in children: time for re-evaluation? | 2001 Mar |
|
Opiate use to control bowel motility may induce chronic daily headache in patients with migraine. | 2001 Mar |
|
Dihydrocodeine--drug of use or misuse? | 2001 May |
|
The analgesic effect of codeine as compared to imipramine in different human experimental pain models. | 2001 May |
|
Selective antibodies to methadone enantiomers: synthesis of (R)- and (R,S)-methadone conjugates and determination by an immunoenzymatic method in human serum. | 2001 May 5 |
|
Application of liquid chromatography to the simultaneous determination of acetylsalicylic acid, caffeine, codeine, paracetamol, pyridoxine, and thiamine in pharmaceutical preparations. | 2001 May-Jun |
|
Regional block and mexiletine: the effect on pain after cancer breast surgery. | 2001 May-Jun |
|
Novel dynamic polymer coating for capillary electrophoresis in nonaqueous methanolic background electrolytes. | 2001 Oct |
|
Incorporation of selegiline metabolites into hair after oral selegiline intake. | 2001 Oct |
|
Spontaneous reports on drug-induced pancreatitis in Denmark from 1968 to 1999. | 2001 Sep |
|
Community pharmacists' experience of over-the-counter medicine misuse in Scotland. | 2001 Sep |
|
Cetirizine inhibits skin reactions but not mediator release in immediate and developing late-phase allergic cutaneous reactions. A double-blind, placebo-controlled study. | 2001 Sep |
|
Rofecoxib versus codeine/acetaminophen in postoperative dental pain: a double-blind, randomized, placebo- and active comparator-controlled clinical trial. | 2001 Sep |
|
Tramadol/acetaminophen combination tablets and codeine/acetaminophen combination capsules for the management of chronic pain: a comparative trial. | 2001 Sep |
|
[Weak opioids]. | 2001 Sep |
Sample Use Guides
In Vivo Use Guide
Sources: https://online.lexi.com/lco/medguides/622452.pdf
Unknown
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:04:29 UTC 2023
by
admin
on
Fri Dec 15 15:04:29 UTC 2023
|
Record UNII |
Q830PW7520
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
N02AA79
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
||
|
WHO-ATC |
N02AJ06
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
2.2
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
||
|
WHO-VATC |
QN02AA79
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
||
|
WHO-ATC |
N02AJ08
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
||
|
CFR |
21 CFR 341.14
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
||
|
CFR |
21 CFR 1308.15
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
||
|
CFR |
21 CFR 341.74
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
||
|
WHO-ATC |
N02AA59
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
||
|
DEA NO. |
9050
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
||
|
CFR |
21 CFR 290.2
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
||
|
WHO-ATC |
R05DA04
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
||
|
WHO-ATC |
N02AJ07
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
||
|
NCI_THESAURUS |
C1657
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
||
|
WHO-VATC |
QR05DA04
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
||
|
NDF-RT |
N0000175690
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
||
|
WHO-VATC |
QN02AA59
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
||
|
LIVERTOX |
NBK548359
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CODEINE
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
PRIMARY | Description: Colourless crystals or a white, crystalline powder; odourless.Solubility: Slightly soluble in water; freely soluble in ethanol (~750 g/l) TS and ether R.Category: Antitussive; analgesic.Storage: Codeine monohydrate should be kept in a tightly closed container, protected from light.Additional information: Codeine monohydrate effloresces slowly in dry air. | ||
|
1673
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
PRIMARY | |||
|
DTXSID20209391
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
PRIMARY | |||
|
CODEINE
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
PRIMARY | |||
|
CHEMBL485
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
PRIMARY | |||
|
SUB26908
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
PRIMARY | |||
|
C383
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
PRIMARY | |||
|
DB00318
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
PRIMARY | |||
|
16714
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
PRIMARY | |||
|
5362471
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
PRIMARY | |||
|
100000090266
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
PRIMARY | |||
|
SUB13424MIG
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
PRIMARY | |||
|
57871
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
PRIMARY | |||
|
Q830PW7520
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
PRIMARY | |||
|
Q830PW7520
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
PRIMARY | |||
|
D003061
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
PRIMARY | |||
|
2670
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
PRIMARY | RxNorm | ||
|
725
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
PRIMARY | |||
|
Codeine
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
PRIMARY | |||
|
6059-47-8
Created by
admin on Fri Dec 15 15:04:29 UTC 2023 , Edited by admin on Fri Dec 15 15:04:29 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
||
|
ANHYDROUS->SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|